{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:03:47Z","timestamp":1791216227175,"version":"4.1.0"},"reference-count":9,"publisher":"Scientific Scholar","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"\n Background & objectives<\/jats:title>\n The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) among the healthcare professionals.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This was a descriptive cross-sectional survey. After taking clearance from the institutional ethics committee 1500 healthcare professionals, who had their vaccination in the past two weeks were selected. They were provided with an online survey proforma regarding adverse events following immunization (AEFIs) of COVID-19 vaccine developed using google forms with an informed consent form affixed to it.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 1036 individuals participated in the study. The mean and median (inter quartile range) age of the participants was 37.7 \u00b111.25 and 35 (29-46) yr, respectively. Of these, 52.1 per cent were female, 29.3 per cent were doctors, 33.4 per cent were nurses and 9.5 per cent were paramedical staff. Forty six per cent participants experienced one or more minor AEFIs such as pain, tenderness, redness, etc<\/jats:italic>. at the injection site. Fatigue (31.75%), generalized feeling of unwell (28.57%), muscle pain (23.16%) and fever (21.71%) were the most commonly reported systemic AEFIs followed by headache (20.07%), dizziness (10.03%) and joint pains (15.25%). Most of them experienced these AEFIs within 24 h of the first dose of administration. About 42 per cent of the participants took oral antipyretics\/analgesics for managing the AEFIs.<\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions<\/jats:title>\n ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated with mild local and systemic AEFIs that were more common after the first dose as compared to the second dose. There adverse events could be dealt with oral over-the-counter medications, with no requirement of hospitalization.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_1221_21","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T06:46:17Z","timestamp":1643697977000},"page":"123-128","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals"],"prefix":"10.25259","volume":"155","author":[{"given":"Sukhpal","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latika","family":"Rohilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvir","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anadeep","family":"Chandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Lal","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Kajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen B.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Devnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karobi","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Pandav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.D.","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R5-18-20241212","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/postgradmedj-2020-138903","article-title":"Will vaccination refusal prolong the war on SARS-CoV-2?","volume":"97","author":"Marcec","year":"2021","journal-title":"Postgrad Med J"},{"key":"R6-18-20241212","doi-asserted-by":"crossref","first-page":"100495","DOI":"10.1016\/j.eclinm.2020.100495","article-title":"Determinants of COVID-19 vaccine acceptance in the US","volume":"26","author":"Malik","year":"2020","journal-title":"EClinicalMedicine"},{"key":"R7-18-20241212","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"R13-18-20241212","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First month of COVID-19 vaccine safety monitoring \u2013United States, December 14, 2020\u2013January 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"key":"R15-18-20241212","doi-asserted-by":"crossref","first-page":"e0250555","DOI":"10.1371\/journal.pone.0250555","article-title":"Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan","volume":"16","author":"El-Elimat","year":"2021","journal-title":"PLoS One"},{"key":"R16-18-20241212","doi-asserted-by":"crossref","first-page":"100012","DOI":"10.1016\/j.lanepe.2020.100012","article-title":"Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications","volume":"1","author":"Paul","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"R17-18-20241212","first-page":"2317","article-title":"Attitudes towards COVID-19 vaccination, vaccine hesitancy and intention to take the vaccine","volume":"19","author":"Cordina","year":"2021","journal-title":"Pharm Pract"},{"key":"R18-18-20241212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/amh.amh_33_21","article-title":"Attitude towards COVID-19 vaccine among the general public in south India: A cross sectional study","volume":"22","author":"Godasi","year":"2021","journal-title":"Arch Ment Health"},{"key":"R19-18-20241212","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-021-00335-2","article-title":"Public attitudes toward COVID-19 vaccination:The role of vaccine attributes, incentives, and misinformation","volume":"6","author":"Kreps","year":"2021","journal-title":"NPJ Vaccines"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.ijmr_1221_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:04:41Z","timestamp":1751497481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/reporting-adverse-events-of-chadox1-ncov-19-coronavirus-vaccine-recombinant-among-the-vaccinated-healthcare-professionals-a-cross-sectional-survey\/"}},"subtitle":["A cross-sectional survey"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_1221_21","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}